
|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
<em>RICTOR</em> Amplification in Lung Cancer
Author(s)Bilal Piperdi, MD
Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.
Advertisement
Bilal Piperdi, MD, Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Albert Einstein College of Medicine, director, Lung Cancer Program, Montefiore Einstein Center for Cancer Care, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked atRICTORamplification to define a subset of patients with lung cancer.
Read more about defining subsets and predicting outcomes in lung cancer > >
Articles in this issue
almost 12 years ago
Angiogenesis Biomarkers Show Potential for Predicting PFS and OS in NSCLCalmost 12 years ago
Tumor Growth Reduced With Cabozantinib Plus Erlotinib in EGFR-Positive NSCLCalmost 12 years ago
Update on Next-Generation Therapies for NSCLCalmost 12 years ago
Adverse Events Associated With CO-1686almost 12 years ago
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLCalmost 12 years ago
Peer Discussion on Maintenance Therapy in NSCLCalmost 12 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under WayAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































